Canadian Biomarker Integration Network for Depression Study

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

April 23, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Major Depressive Disorder
Interventions
DRUG

escitalopram

Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.

DRUG

aripiprazole

At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.

Trial Locations (6)

T2N 2T9

University of Calgary, Calgary

V6T 2A1

University of British Columbia, Vancouver

L8P 3B6

McMaster University, Hamilton

K7L 4X3

Queen's University, Kingston

M5G 2C4

University Health Network, Toronto

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

University of Toronto

OTHER

collaborator

University of Calgary

OTHER

collaborator

University of British Columbia

OTHER

collaborator

McGill University

OTHER

collaborator

Queen's University

OTHER

collaborator

Centre for Addiction and Mental Health

OTHER

collaborator

McMaster University

OTHER

lead

University Health Network, Toronto

OTHER

NCT01655706 - Canadian Biomarker Integration Network for Depression Study | Biotech Hunter | Biotech Hunter